drugset / Trial / NCT01202110

Early Propranolol After Traumatic Brain Injury: Phase II

NCT01202110

Phase 2 Terminated 10 enrolled Cedars-Sinai Medical Center
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to determine in patients with traumatic brain injury (TBI) the safe dosing of propranolol. Safety will be measured by episodes of bradycardia (heart rate \< 60 beats per minute), hypotension (defined as systolic blood pressure \< 90) or decreased cerebral perfusion pressure (defined as CPP less than 60mmHg) that are refractive to Brain Trauma Foundation guidelines for treatment. A no-treatment arm will establish the number of episodes of bradycardia, hypotension and reduced cerebral pressure refractory to treatment that occur without propranolol.

Timeline

Start
2010-06
Primary completion
2015-02
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Propranolol Small molecule 1 mg Intravenous